title: [Study of meningeal carcinomatosis: diagnosis and treatment].
abstract: Thirty-four patients with meningeal carcinomatosis were treated at The Center for Adult Diseases, Osaka, from 1984 through 1990. The major origin of meningeal carcinomatosis was carcinoma of the lung (14 cases) and breast (8 cases). The most frequent histological type of carcinoma was adenocarcinoma (23 cases). Twenty cases still had active lesions and/or primary lesions in the lung, liver or bone at the time of diagnosis of the meningeal carcinomatosis. The primary lesions were treated surgically in 22 cases, with chemotherapy in 4 cases and with radiotherapy in 2 cases. Metastatic brain tumors were treated by surgical removal followed by chemo-radiotherapy in 12 cases, and with radiotherapy alone in 2 cases. The interval from the time of diagnosis of the primary lesion to the time of diagnosis of the meningeal carcinomatosis varied from one month to eight years, and the interval between surgical removal of metastatic brain tumors and the diagnosis of meningeal carcinomatosis ranged from 0 to 3 years. With regard to the diagnosis of meningeal carcinomatosis, positive cytology was seen in initial standard lumbar puncture in 32 of the 34 patients. CT scan showed abnormal findings in 28 of the 34 patients, including ventricular dilatation only (12 cases), and small enhancing lesions along the CSF space (12 cases). The EEG showed abnormal patterns in 14 of 15 cases. Intrathecal chemotherapy with methotrexate alone or combined methotrexate with cytosine arabinoside via the Ommaya reservoir or standard lumbar puncture alternately with or without radiation therapy was successful as treatment, and 22 of 29 treated patients showed symptomatic improvement of the meningeal irritation.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Neurosurgery, Center for Adult Diseases, Osaka, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Nakagawa
authors.forename: A
authors.initials: A
authors.lastname: Murasawa
authors.forename: S
authors.initials: S
authors.lastname: Nakajima
authors.forename: Y
authors.initials: Y
authors.lastname: Nakajima
authors.forename: S
authors.initials: S
authors.lastname: Izumoto
authors.forename: S
authors.initials: S
authors.lastname: Kubo
authors.forename: T
authors.initials: T
authors.lastname: Hayakawa
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000473:pathology*; D003131:Combined Modality Therapy; D004569:Electroencephalography; D005260:Female; D006801:Humans; D007278:Injections, Spinal; D008175:Lung Neoplasms / Q000473:pathology*; D008297:Male; D008577:Meningeal Neoplasms / Q000175:diagnosis / Q000556:secondary* / Q000628:therapy; D008581:Meningitis / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D013129:Spinal Puncture; D014057:Tomography, X-Ray Computed
chemical_list: D008727:Methotrexate